Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xtent’s CUSTOM II trial

This article was originally published in The Gray Sheet

Executive Summary

Delivery of longest stent ever with a single catheter achieved in first stages of Xtent's 70-patient feasibility trial examining the use of the firm's Biolimus A9-eluting stent to treat long-lesion, multi-lesion and multi-vessel disease. The firm also noted that physicians in the study used a single catheter to treat multiple lesions in multiple arteries, a first in coronary stenting. The firm believes that its ability to treat long lesions will differentiate it from the competition (1"The Gray Sheet" Oct. 24, 2005, p. 21)...
Advertisement

Related Content

CEO Chat: Xtent Touts Customized Drug-Eluting Stent Delivery System At TCT
CEO Chat: Xtent Touts Customized Drug-Eluting Stent Delivery System At TCT
Advertisement
UsernamePublicRestriction

Register

MT023094

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel